Buscar completed the acquisition of a 70% stake in Armorgenix.

Buscar, a publicly traded diversified holding company, completed the acquisition of a 70% stake in Armorgenix, a company specializing in the distribution and planned production of advanced pharmaceutical products. Financial terms were not disclosed. "Adding Armorgenix to our family of companies is a pivotal milestone for Buscar. This acquisition not only diversifies our portfolio with innovative pharmaceutical solutions but also reinforces our commitment to tackling global challenges, from environmental sustainability to advanced healthcare. We are excited to collaborate with Armorgenix's team to bring life-enhancing products to North American markets and deliver exceptional value to our shareholders," Alexander Dekhtyar, Buscar CEO.